{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T02:15:22Z","timestamp":1795054522916,"version":"4.10.2"},"reference-count":38,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,12]]},"abstract":"<jats:p>Melanoma is an aggressive cancer. Outcomes can vary significantly for lesions within the same pathological stage \u2013 a problem of increasing relevance with the promise of adjuvant treatments on the basis of immune checkpoint modulators and targeted therapies. The use of a panel of prognostic molecular biomarkers as an adjunct to stage represents a possible solution. Immunohistochemistry-based biomarkers offer greater potential for translation into clinical practice than biomarkers utilizing more complex methods. Many immunohistochemistry-based biomarkers have been identified through discovery studies, but rigorous validation of these is scarce. We take the first steps towards validating a combination of three such biomarkers in a prognostic panel \u2013 5hmC, ki-67 and p16. Immunohistochemistry was performed on a cohort of 50 melanomas to determine the expression of 5hmC, ki-67 and p16. 5hmC and p16 showed statistically significant differences in metastasis-free survival between low-score and high-score groups, whereas the use of all three biomarkers together with stage could predict the 5-year metastasis risk more accurately than stage alone. Our results suggest that the use of multimarker panels to improve the accuracy of prognostic predictions is feasible and worthy of further study. We have shown that a small immunohistochemistry-based panel utilizing simple, inexpensive, reproducible methods can be an effective adjunct to stage in prognostic prediction. A follow-up study consisting of a large cohort of melanomas is now indicated to continue the development of the prognostic panel.<\/jats:p>","DOI":"10.1097\/cmr.0000000000000293","type":"journal-article","created":{"date-parts":[[2016,9,3]],"date-time":"2016-09-03T12:59:57Z","timestamp":1472907597000},"page":"580-587","source":"Crossref","is-referenced-by-count":6,"title":["A small multimarker panel using simple immunohistochemistry methods is an adjunct to stage for cutaneous melanoma prognosis"],"prefix":"10.1097","volume":"26","author":[{"given":"Sam T.","family":"Romaine","sequence":"first","affiliation":[{"name":"Department of Cancer Studies, University of Leicester"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Wells-Jordan","sequence":"additional","affiliation":[{"name":"EMPATH Department of Cellular Pathology, University Hospitals of Leicester, Leicester Royal Infirmary, Leicester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tracey","family":"de Haro","sequence":"additional","affiliation":[{"name":"EMPATH Department of Cellular Pathology, University Hospitals of Leicester, Leicester Royal Infirmary, Leicester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avni","family":"Dave-Thakrar","sequence":"additional","affiliation":[{"name":"EMPATH Department of Cellular Pathology, University Hospitals of Leicester, Leicester Royal Infirmary, Leicester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"North","sequence":"additional","affiliation":[{"name":"EMPATH Department of Cellular Pathology, University Hospitals of Leicester, Leicester Royal Infirmary, Leicester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James H.","family":"Pringle","sequence":"additional","affiliation":[{"name":"Department of Cancer Studies, University of Leicester"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald","family":"Saldanha","sequence":"additional","affiliation":[{"name":"Department of Cancer Studies, University of Leicester"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230902","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1038\/jid.2010.149","article-title":"biomarkers: the useful and the not so useful \u2013 an assessment of molecular prognostic markers for cutaneous melanoma","volume":"130","author":"Gould Rothberg","year":"2010","journal-title":"J Invest Dermatol"},{"key":"R2-20230902","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s00428-013-1526-x","article-title":"Tissue prognostic biomarkers in primary cutaneous melanoma","volume":"464","author":"Mandal\u00e0","year":"2014","journal-title":"Virchows Arch"},{"key":"R3-20230902","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1111\/j.1365-2559.2011.03910.x","article-title":"Prognostic tissue markers in melanoma","volume":"60","author":"Moore","year":"2012","journal-title":"Histopathology"},{"key":"R4-20230902","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/S1470-2045(15)70122-1","article-title":"Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial","volume":"16","author":"Eggermont","year":"2015","journal-title":"Lancet Oncol"},{"key":"R5-20230902","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1158\/1078-0432.CCR-13-3316","article-title":"Development of a prognostic genetic signature to predict the metastatic risk associated with cutaneous melanoma","volume":"21","author":"Gerami","year":"2015","journal-title":"Clin Cancer Res"},{"key":"R6-20230902","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/j.jaad.2015.01.009","article-title":"Gene expression profiling for molecular staging of cutaneous melanoma in patients undergoing sentinel lymph node biopsy","volume":"72","author":"Gerami","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"R8-20230902","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1097\/DAD.0b013e31828a2ec5","article-title":"Cutaneous malignant melanoma: update on diagnostic and prognostic biomarkers","volume":"36","author":"Abbas","year":"2014","journal-title":"Am J Dermatopathol"},{"key":"R9-20230902","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1126\/science.1170116","article-title":"Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1","volume":"324","author":"Tahiliani","year":"2009","journal-title":"Science"},{"key":"R10-20230902","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1126\/science.1169786","article-title":"The nuclear DNA base 5-hydroxymethylcytosine is present in Purkinje neurons and the brain","volume":"324","author":"Kriaucionis","year":"2009","journal-title":"Science"},{"key":"R11-20230902","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1038\/nature09303","article-title":"Role of Tet proteins in 5mC to 5hmC conversion, ES-cell self-renewal and inner cell mass specification","volume":"466","author":"Ito","year":"2010","journal-title":"Nature"},{"key":"R12-20230902","doi-asserted-by":"crossref","first-page":"7360","DOI":"10.1158\/0008-5472.CAN-11-2023","article-title":"5-Hydroxymethylcytosine is strongly depleted in human cancers but its levels do not correlate with IDH1 mutations","volume":"71","author":"Jin","year":"2011","journal-title":"Cancer Res"},{"key":"R13-20230902","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/j.cell.2012.07.033","article-title":"Loss of 5-hydroxymethylcytosine is an epigenetic hallmark of melanoma","volume":"150","author":"Lian","year":"2012","journal-title":"Cell"},{"key":"R14-20230902","doi-asserted-by":"crossref","first-page":"627","DOI":"10.18632\/oncotarget.316","article-title":"Global 5-hydroxymethylcytosine content is significantly reduced in tissue stem\/progenitor cell compartments and in human cancers","volume":"2","author":"Haffner","year":"2011","journal-title":"Oncotarget"},{"key":"R15-20230902","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"R16-20230902","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1038\/modpathol.2012.188","article-title":"Proliferation indices of phosphohistone H3 and Ki67: strong prognostic markers in a consecutive cohort with stage I\/II melanoma","volume":"26","author":"Nielsen","year":"2013","journal-title":"Modern Pathol"},{"key":"R17-20230902","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1136\/jcp.2003.010777","article-title":"Prognostic value of proliferation in invasive breast cancer: a review","volume":"57","author":"van Diest","year":"2004","journal-title":"J Clin Pathol"},{"key":"R18-20230902","first-page":"76","article-title":"Biological behavior due to cell proliferation markers of gastrointestinal stromal tumors","volume":"58","author":"Men\u00e9ndez","year":"2011","journal-title":"Hepatogastroenterology"},{"key":"R19-20230902","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1309\/HXUNAG34B3CEFDU8","article-title":"Prognostic significance of the mitotic index using the mitosis marker anti-phosphohistone H3 in meningiomas","volume":"128","author":"Kim","year":"2007","journal-title":"Am J Clin Pathol"},{"key":"R20-20230902","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1097\/01.pas.0000152129.81363.d2","article-title":"Description of a novel system for grading of endometrial carcinoma and comparison with existing grading systems","volume":"29","author":"Alkushi","year":"2005","journal-title":"Am J Surg Pathol"},{"key":"R21-20230902","first-page":"13","article-title":"Diagnostic and prognostic biomarkers in melanoma","volume":"7","author":"Weinstein","year":"2014","journal-title":"J Clin Aesthet Dermatol"},{"key":"R22-20230902","doi-asserted-by":"crossref","first-page":"6199","DOI":"10.1200\/JCO.2009.23.4799","article-title":"Final version of 2009 AJCC melanoma staging and classification","volume":"27","author":"Balch","year":"2009","journal-title":"J Clin Oncol"},{"key":"R23-20230902","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1111\/j.1600-0560.2011.01858.x","article-title":"Immunohistochemical dual staining as an adjunct in assessment of mitotic activity in melanoma","volume":"39","author":"Ikenberg","year":"2012","journal-title":"J Cutan Pathol"},{"key":"R24-20230902","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1097\/DAD.0b013e31823135a3","article-title":"pHH3 immunostaining improves interobserver agreement of mitotic index in thin melanomas","volume":"34","author":"Schimming","year":"2012","journal-title":"Am J Dermatopathol"},{"key":"R25-20230902","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1097\/PAS.0b013e31827e50fa","article-title":"Mitotic rate in melanoma: prognostic value of immunostaining and computer-assisted image analysis","volume":"37","author":"Hale","year":"2013","journal-title":"Am J Surg Pathol"},{"key":"R26-20230902","doi-asserted-by":"crossref","first-page":"3245","DOI":"10.1200\/JCO.1999.17.10.3245","article-title":"Counseling and DNA testing for individuals perceived to be genetically predisposed to melanoma: a consensus statement of the Melanoma Genetics Consortium","volume":"17","author":"Kefford","year":"1999","journal-title":"J Clin Oncol"},{"key":"R27-20230902","doi-asserted-by":"crossref","first-page":"41424","DOI":"10.1074\/jbc.M105299200","article-title":"Mutations in the INK4a\/ARF melanoma susceptibility locus functionally impair p14ARF","volume":"276","author":"Rizos","year":"2001","journal-title":"J Biol Chem"},{"key":"R28-20230902","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1080\/00313020701684409","article-title":"Reduced expression of p16 and p27 is correlated with tumour progression in cutaneous melanoma","volume":"39","author":"Sanki","year":"2007","journal-title":"Pathology"},{"key":"R29-20230902","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1186\/s13000-015-0431-9","article-title":"A p16-Ki-67-HMB45 immunohistochemistry scoring system as an ancillary diagnostic tool in the diagnosis of melanoma","volume":"10","author":"Uguen","year":"2015","journal-title":"Diagn Pathol"},{"key":"R30-20230902","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.1002\/ijc.21608","article-title":"p16 expression in primary malignant melanoma is associated with prognosis and lymph node status","volume":"118","author":"Mihic-Probst","year":"2006","journal-title":"Int J Cancer"},{"key":"R31-20230902","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1309\/AJCP52YVYCTLUOPI","article-title":"Immunohistochemical evaluation of p16INK4A, E-cadherin, and cyclin D1 expression in melanoma and Spitz tumors","volume":"133","author":"George","year":"2010","journal-title":"Am J Clin Pathol"},{"key":"R32-20230902","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1136\/jclinpath-2013-202127","article-title":"Immunohistochemical analysis of molecular drivers in melanoma identifies p16 as an independent prognostic biomarker","volume":"67","author":"Lade-Keller","year":"2014","journal-title":"J Clin Pathol"},{"key":"R33-20230902","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1093\/jnci\/dji237","article-title":"Reporting recommendations for tumor marker prognostic studies (REMARK)","volume":"97","author":"McShane","year":"2005","journal-title":"J Natl Cancer Inst"},{"key":"R34-20230902","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1016\/S0895-4356(96)00236-3","article-title":"A simulation study of the number of events per variable in logistic regression analysis","volume":"49","author":"Peduzzi","year":"1996","journal-title":"J Clin Epidemiol"},{"key":"R35-20230902","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/1523-1747.ep12312431","article-title":"MIB-1 proliferative activity is a significant prognostic factor in primary thick cutaneous melanomas","volume":"105","author":"Ramsay","year":"1995","journal-title":"J Invest Dermatol"},{"key":"R36-20230902","doi-asserted-by":"crossref","first-page":"8048","DOI":"10.1200\/JCO.2005.02.0735","article-title":"Biologic and prognostic significance of dermal Ki67 expression, mitoses, and tumorigenicity in thin invasive cutaneous melanoma","volume":"23","author":"Gimotty","year":"2005","journal-title":"J Clin Oncol"},{"key":"R37-20230902","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1186\/1471-2407-10-140","article-title":"Ki-67 expression is superior to mitotic count and novel proliferation markers PHH3, MCM4 and mitosin as a prognostic factor in thick cutaneous melanoma","volume":"10","author":"Ladstein","year":"2010","journal-title":"BMC Cancer"},{"key":"R38-20230902","doi-asserted-by":"crossref","first-page":"3622","DOI":"10.1200\/JCO.2001.19.16.3622","article-title":"Prognostic factors analysis of 17\u2009600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system","volume":"19","author":"Balch","year":"2001","journal-title":"J Clin Oncol"},{"key":"R39-20230902","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1136\/bmj.324.7336.539","article-title":"Evidence base of clinical diagnosis: the architecture of diagnostic research","volume":"324","author":"Sackett","year":"2002","journal-title":"BMJ"}],"container-title":["Melanoma Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00008390-201612000-00005","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,2]],"date-time":"2023-09-02T03:17:44Z","timestamp":1693624664000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00008390-201612000-00005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12]]},"references-count":38,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.1097\/cmr.0000000000000293","relation":{},"ISSN":["0960-8931"],"issn-type":[{"value":"0960-8931","type":"print"}],"subject":[],"published":{"date-parts":[[2016,12]]}}}